Pharmafile Logo

Portfolio analysis: Making Go/No-Go decisions to optimise the portfolio

Tuesday 20th March 2018 11:00 EST / 16:00 GMT / 17:00 CEST

Register now: http://bit.ly/2FnXsFx

When a pharma company is either considering acquiring a new agent, or developing one in-house, marketers need to understand the impact on the overall portfolio and decide whether to make a go or no-go decision on that asset.Join US Directors Tom Nolte and Melinda Shorr for this webinar which shows you how market research insights allow you to make confident go/no-go decisions in portfolio planning.

They will address:

Why portfolios need to adapt and change
Success today is not necessarily success tomorrow. Depth and diversification are essential to a strong portfolio – we explore the reasons why you need to actively plan for the future.

Considerations for Go/No-go research design for portfolio planning
We show you how to create an effective market research programme – what stakeholders needs to be involved in the planning process, what questions need to be asked and what methods can be used.

Determining value and magnitude metrics
We discuss the criteria by which additions to a pipeline fit into the key metrics – what value they bring to the portfolio and the size of that opportunity (magnitude). Conversely we will look at what the removal of an asset has on the overall portfolio.

Speed of decision-making
If agents are being developed in-house, evaluations can be made slowly and rigorously. When agents are being acquired, the decision to go or no-go often needs to be made quickly. We discuss the impact on market research design. 
Our presenters will also use a case study to demonstrate how market research insights support better decision-making on new agents in a portfolio.

Question and answer session
Following the presentation there will be a live Q&A where they will address any specific challenges you have encountered or concerns you may have about conducting portfolio analysis studies. We welcome you to submit your questions in advance when you register.

Register now: http://bit.ly/2FnXsFx

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...

Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot

This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across...

Research conducted for Johnson and Johnson published in scientific journal

Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

Connecting our Inizio Advisory capabilities to help a client address a threat to the brand, guide strategy and improve brand performance

The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address...

Autoimmune conditions: Living With syndicated patient reports

The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our...

How we elevated HCP market research engagement and insights using AI avatars for an immersive experience

Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver...

How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution

PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...

Latest European developments and new talent at Research Partnership

Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its...